Profile data is unavailable for this security.
About the company
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
- Revenue in USD (TTM)39.21m
- Net income in USD-311.35m
- Incorporated2015
- Employees238.00
- LocationKymera Therapeutics Inc500 North Beacon Street, 4Th FloorWATERTOWN 02472United StatesUSA
- Phone+1 (857) 285-5314
- Fax+1 (302) 655-5049
- Websitehttps://www.kymeratx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apogee Therapeutics Inc | 0.00 | -255.84m | 5.02bn | 261.00k | -- | 5.47 | -- | -- | -4.22 | -4.22 | 0.00 | 13.21 | 0.00 | -- | -- | 0.00 | -30.26 | -- | -31.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.46 | -- | -- | -- |
| Celcuity Inc | 0.00 | -162.72m | 5.19bn | 87.00 | -- | 41.50 | -- | -- | -3.67 | -3.67 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -43.45 | -42.61 | -47.58 | -45.75 | -- | -- | -- | -- | -- | -48.30 | 0.7325 | -- | -- | -- | -75.26 | -- | -8.05 | -- |
| CG Oncology Inc | 4.04m | -161.00m | 5.20bn | 142.00 | -- | 6.60 | -- | 1,286.80 | -2.08 | -2.08 | 0.0523 | 9.33 | 0.0052 | -- | 5.50 | 28,450.71 | -20.82 | -- | -21.55 | -- | -16.31 | -- | -3,985.03 | -- | 24.58 | -- | 0.004 | -- | 254.70 | -- | -82.87 | -- | -- | -- |
| Scholar Rock Holding Corp | 0.00 | -353.43m | 5.45bn | 196.00 | -- | 19.20 | -- | -- | -3.15 | -3.15 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -119.63 | -45.06 | -144.40 | -51.62 | -- | -- | -- | -1,134.62 | -- | -- | 0.2891 | -- | -- | -- | -48.56 | -- | -49.93 | -- |
| Immunovant Inc | 0.00 | -464.20m | 5.51bn | 362.00 | -- | 5.58 | -- | -- | -2.68 | -2.68 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -63.01 | -47.00 | -69.35 | -51.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -59.58 | -- | 89.57 | -- |
| Cogent Biosciences Inc | 0.00 | -277.80m | 6.01bn | 258.00 | -- | 10.90 | -- | -- | -2.15 | -2.15 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -51.99 | -55.96 | -57.41 | -62.16 | -- | -- | -- | -- | -- | -- | 0.2594 | -- | -- | -- | -37.96 | -- | -- | -- |
| Protagonist Therapeutics Inc | 46.02m | -130.15m | 6.05bn | 132.00 | -- | 9.65 | -- | 131.50 | -2.04 | -2.04 | 0.7239 | 9.82 | 0.0651 | -- | 12.10 | 348,606.10 | -18.42 | -8.51 | -19.72 | -9.31 | -- | -- | -282.83 | -31.44 | -- | -- | 0.00 | -- | -89.41 | 9.96 | -147.29 | -- | 27.55 | -- |
| Arcellx Inc | 22.29m | -228.93m | 6.68bn | 209.00 | -- | 16.46 | -- | 299.93 | -4.06 | -4.06 | 0.3945 | 6.95 | 0.0339 | -- | 7.31 | 106,631.60 | -34.81 | -28.60 | -42.17 | -34.05 | -- | -- | -1,027.26 | -274.64 | -- | -- | 0.00 | -- | -79.35 | -- | -113.26 | -- | 21.25 | -- |
| Belite Bio Inc (ADR) | 0.00 | -64.60m | 6.99bn | 25.00 | -- | 9.08 | -- | -- | -1.93 | -1.93 | 0.00 | 19.59 | 0.00 | -- | -- | -- | -13.85 | -23.54 | -13.94 | -24.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -114.73 | -- | -- | -- |
| Kymera Therapeutics Inc | 39.21m | -311.35m | 7.03bn | 238.00 | -- | 4.43 | -- | 179.30 | -3.68 | -3.68 | 0.4642 | 19.42 | 0.0288 | -- | -- | 164,747.90 | -22.89 | -24.17 | -24.23 | -27.06 | -- | -- | -794.06 | -329.38 | -- | -- | 0.0021 | -- | -16.70 | 2.87 | -39.08 | -- | -30.75 | -- |
| Cytokinetics, Inc. | 88.04m | -784.96m | 7.67bn | 673.00 | -- | -- | -- | 87.11 | -6.53 | -6.53 | 0.733 | -5.37 | 0.0623 | -- | 5.12 | 130,815.80 | -55.55 | -49.49 | -64.23 | -55.60 | -- | -- | -891.60 | -897.66 | -- | -11.95 | 2.33 | -- | 376.56 | 9.54 | -33.15 | -- | 17.55 | -- |
| Nuvalent Inc | 0.00 | -425.38m | 8.07bn | 228.00 | -- | 6.43 | -- | -- | -5.85 | -5.85 | 0.00 | 15.96 | 0.00 | -- | -- | 0.00 | -33.30 | -27.97 | -35.31 | -29.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.13 | -- | -- | -- |
| ICON PLC | 8.10bn | 599.48m | 8.41bn | 39.80k | 14.90 | 0.9015 | 8.51 | 1.04 | 7.40 | 7.40 | 101.04 | 122.25 | 0.4806 | -- | 3.00 | 193,379.50 | 3.56 | 3.70 | 4.33 | 4.46 | 28.15 | 29.00 | 7.40 | 7.41 | -- | 5.94 | 0.2675 | -- | 1.99 | 24.17 | 29.26 | 16.18 | 27.11 | -- |
| Vaxcyte Inc | 0.00 | -766.63m | 8.65bn | 507.00 | -- | 2.93 | -- | -- | -5.63 | -5.63 | 0.00 | 20.49 | 0.00 | -- | -- | 0.00 | -23.54 | -24.62 | -24.86 | -26.20 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -65.25 | -- | 118.08 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.02bn | -144.34m | 8.84bn | 18.30k | -- | 2.79 | 33.85 | 2.20 | -2.96 | -2.96 | 80.79 | 64.30 | 0.5477 | 9.04 | 5.62 | 219,419.80 | -1.94 | 3.42 | -2.28 | 4.01 | 34.98 | 36.22 | -3.54 | 6.37 | 1.02 | 3.43 | 0.3999 | 0.00 | -0.8545 | 6.55 | -1,501.75 | -- | 5.64 | -- |
Data as of Mar 04 2026. Currency figures normalised to Kymera Therapeutics Inc's reporting currency: US Dollar USD
68.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Dec 2025 | 8.66m | 10.97% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 8.61m | 10.91% |
| Avoro Capital Advisor LLCas of 31 Dec 2025 | 7.47m | 9.47% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 6.09m | 7.72% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.77m | 7.31% |
| BVF Partners LPas of 31 Dec 2025 | 5.50m | 6.97% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.25m | 5.39% |
| Wellington Management Co. LLPas of 31 Dec 2025 | 4.23m | 5.35% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 2.21m | 2.80% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2025 | 1.56m | 1.98% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
